Navigation Links
The Patent Board, IP Tracking and Analysis Firm, Ranks Heska's Science Strength in Biotechnology Industry Top 50
Date:10/6/2011

LOVELAND, Colo., Oct. 6, 2011 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA), a provider of advanced veterinary diagnostic and other specialty veterinary products, today announced The Patent Board, a leading independent provider of best practices research, tools and metrics for patent analysis and intellectual property investment (http://www.patentboard.com), has ranked Heska's Science Strength in the top 50 of the Biotechnology industry.  More information can be obtained at the following weblink: http://online.wsj.com/mdc/public/page/2_3022-macromkt.html.

"We are pleased a respected third party has chosen to recognize our Science Strength," said Dr. Robert Grieve, Heska's Chairman and CEO.  "The quality of our scientific efforts and the potential value of our substantial intellectual property value are assets we feel are often overlooked."

As of September 30, 2011, Heska owns, co-owns or has rights to 196 issued U.S. patents and six pending U.S. patent applications with a corresponding foreign patent portfolio including 131 issued foreign patents and 21 patent applications in various foreign countries.  Heska's issued and pending patent portfolios primarily relate to heartworm control, flea control, allergy, infectious disease vaccines, diagnostic and detection tests, immunomodulators, instrumentation, nutrition, pain control and vaccine delivery technologies.

About Heska

Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products.  Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines.  The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians.  For further information on Heska and its products, visit the company's website at www.heska.com.


'/>"/>
SOURCE Heska Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value
2. Particle Sciences Granted Patent on Self Sterilizing Medical Devices
3. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Non-Infringement of Johnson & Johnson Patent
4. Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
5. Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma
6. Watson Confirms Amphastar Patent Lawsuit
7. PLC Receives Two Additional U.S. Patents and First Japanese Patent For Its RenalGuard® Technology
8. MedWaves, Incorporated Announces Receipt of Taiwan Food and Drug Administration (TFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices
9. Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing
10. ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders
11. Silence Therapeutics Announces Issuance of Japanese Patent for Screening Therapeutics Against Key Pathway Associated with Cancer and Other Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
(Date:8/2/2017)...   Marshall County Hospital in Benton, Kentucky has added ... hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for "total room ultraviolet ... such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... ... services to communities in east Texas, is launching a regional charity effort to ... Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 ...
(Date:8/18/2017)... Bedford, TX (PRWEB) , ... August 18, 2017 , ... ... serves communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized ... her husband. , In early June of this year, Christina and her children returned ...
(Date:8/18/2017)... ... 2017 , ... Alcovit, a lime-flavored beverage that rids the body of toxins ... product now available through Jet.com. , After 25 years of development, the company ... designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Dangerous Inheritance”: a ... author, Diane Winters. Diane is from Southwest Nebraska where she was raised on ... and family. The story is fictional, but the friendships and mantra of ‘neighbors ...
(Date:8/18/2017)... ... August 18, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, ... yet effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , ...
Breaking Medicine News(10 mins):